Literature DB >> 2492306

Fecal isolation of Pseudomonas aeruginosa from patients with cystic fibrosis.

U Agnarsson1, S Glass, J R Govan.   

Abstract

Fecal isolation of Pseudomonas aeruginosa was observed in 8 of 10 patients with cystic fibrosis who at the time of sampling also exhibited colonization of the respiratory tract. In contrast, P. aeruginosa cells were isolated at low frequency (9.1%) from the stools of 44 patients with cystic fibrosis with no previous history of chronic colonization. The results of this study suggest that the gastrointestinal tract is not a significant chronic reservoir of P. aeruginosa prior to pulmonary colonization.

Entities:  

Mesh:

Year:  1989        PMID: 2492306      PMCID: PMC267240          DOI: 10.1128/jcm.27.1.96-98.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Epidemiological studies of Pseudomonas species in patients with leukemia.

Authors:  G P Bodey
Journal:  Am J Med Sci       Date:  1970-08       Impact factor: 2.378

Review 2.  Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.

Authors:  G B Pier
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

3.  The fecal microflora and bile acids in children with cystic fibrosis.

Authors:  C C Roy; G Delage; A Fontaine; L Robitaille; L Chartrand; A Weber; C L Morin
Journal:  Am J Clin Nutr       Date:  1979-12       Impact factor: 7.045

4.  Revised pyocin typing method for Pseudomonas aeruginosa.

Authors:  J A Fyfe; G Harris; J R Govan
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

5.  Faecal carriage of Pseudomonas aeruginosa in newborn infants.

Authors:  H Yoshioka; K Fujita; S Maruyama
Journal:  J Hosp Infect       Date:  1983-03       Impact factor: 3.926

6.  Nosocomial infections in the immunocompromised adult.

Authors:  L S Young
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

7.  Bacteriology of the maxillary sinuses in patients with cystic fibrosis.

Authors:  E D Shapiro; G J Milmoe; E R Wald; J B Rodnan; A D Bowen
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

8.  Acetamide broth for isolation of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  N M Kelly; F R Falkiner; C T Keane
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

9.  Oral colonization and susceptibility testing of Pseudomonas aeruginosa oral isolates from cystic fibrosis patients.

Authors:  R A Lindemann; M G Newman; A K Kaufman; T V Le
Journal:  J Dent Res       Date:  1985-01       Impact factor: 6.116

Review 10.  Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Authors:  T L Pitt
Journal:  J R Soc Med       Date:  1986       Impact factor: 18.000

View more
  5 in total

Review 1.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

2.  Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets.

Authors:  G Döring; H Bareth; A Gairing; C Wolz; K Botzenhart
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

Review 3.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

4.  Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice.

Authors:  J B Boerema; F T Willems
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  Interactions between the gut microbiome and host gene regulation in cystic fibrosis.

Authors:  Gargi Dayama; Sambhawa Priya; David E Niccum; Alexander Khoruts; Ran Blekhman
Journal:  Genome Med       Date:  2020-01-28       Impact factor: 11.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.